Zimmer Biomet Holdings Inc (NYSE:ZBH) announced a quarterly dividend on Monday, March 12th, RTT News reports. Investors of record on Thursday, March 29th will be given a dividend of 0.24 per share by the medical equipment provider on Monday, April 30th. This represents a $0.96 annualized dividend and a yield of 0.81%.
Zimmer Biomet has a dividend payout ratio of 12.0% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Zimmer Biomet to earn $8.38 per share next year, which means the company should continue to be able to cover its $0.96 annual dividend with an expected future payout ratio of 11.5%.
Shares of Zimmer Biomet (NYSE:ZBH) traded down $2.60 during trading hours on Monday, hitting $118.26. 1,877,908 shares of the company traded hands, compared to its average volume of 1,343,936. The company has a current ratio of 1.50, a quick ratio of 0.81 and a debt-to-equity ratio of 0.76. The stock has a market cap of $24,240.00, a P/E ratio of 13.30, a PEG ratio of 2.13 and a beta of 1.13. Zimmer Biomet has a fifty-two week low of $108.03 and a fifty-two week high of $133.49.
Several equities research analysts recently commented on ZBH shares. SunTrust Banks upped their price target on shares of Zimmer Biomet to $142.00 and gave the company a “buy” rating in a research report on Monday, January 29th. Canaccord Genuity restated a “hold” rating and issued a $125.00 price target on shares of Zimmer Biomet in a research report on Tuesday, December 19th. Oppenheimer restated a “buy” rating on shares of Zimmer Biomet in a research report on Tuesday, December 19th. Deutsche Bank upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price target for the company in a research report on Tuesday, November 14th. Finally, Zacks Investment Research downgraded shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday, November 20th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $141.06.
In related news, insider Bryan C. Hanson acquired 25,077 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were purchased at an average price of $119.68 per share, for a total transaction of $3,001,215.36. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Chad F. Phipps sold 20,826 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $115.95, for a total transaction of $2,414,774.70. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Zimmer Biomet Holdings Inc Announces Quarterly Dividend of $0.24 (ZBH)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/03/12/zimmer-biomet-holdings-inc-announces-quarterly-dividend-of-0-24-zbh.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.